Australian biotech sector crafts response to R&D Tax Incentive Review

11 October 2016

Trade group AusBiotech members are invited to gather at briefings in Sydney, Brisbane and Melbourne to contribute to the crafting of the industry’s response to Australia’s ‘ Ferris, Finkel, Fraser’ Review of the Research & Development (R&D) Tax Incentive.

The Report’s recent launch has already drawn a strong response from industry with a package of recommendations that include placing a A$2 million ($1.5 million) cap on the refundable component of the program that would disadvantage a significant portion of small- and medium-sized enterprises (SMEs) in the sector.

The Report’s launch marked the commencement of a consultation period, which is now open until 28 October with feedback invited on the six recommendations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK